Project Oncology®

Targeting CD123 in AML: The Latest Therapeutic Advancements

Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data

Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data

AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy

AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy

Chemotherapy Strategies for Metastatic PDAC

Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care

Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management

Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings

Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols

Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers

Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01

Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases

Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial

Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results

Poster Pearl: Elacestrant + Abemaciclib for ER+/HER2- Metastatic Breast Cancer

Investigating the Impact of Momelotinib on Myelofibrosis Patients: A Poster from ASH

The Long-Term Safety of Momelotinib for Myelofibrosis: A Poster from ASH

Enhancing Outcomes in Relapsed/Refractory B-ALL with CAR T-Cell Therapy

Selecting High-Risk Mantle Cell Lymphoma Patients for CAR T-Cell Therapy

Uncovering Unmet Needs in Relapsed/Refractory ALL Care

Momelotinib vs. Ruxolitinib: Comparing Efficacy in Myelofibrosis and Anemia Patients

Insights from ICARUS-Lung01: Efficacy and Safety of Dato-DXd for NSCLC

The Promise of MCED Testing: Easing the Burden of Cancer Screening Anxiety

Optimizing Biomarker Testing to Guide Treatment Selection for Metastatic Colorectal Cancer

Optimizing Biomarker Testing to Guide Treatment Selection for Metastatic Colorectal Cancer

Practical Applications for Quality Improvement in Myelofibrosis Management: A Video Brief on Lessons Learned

An Introduction to Squamous Cell Carcinoma of the Head and Neck

A Pre-Conference Perspective of SNMMI 2024

A Pre-Conference Perspective of SNMMI 2024

An Introduction to Squamous Cell Carcinoma of the Head and Neck

EMERALD Trial: An Analysis of Key Biomarkers and Patient Subgroups

EMERALD Trial: An Analysis of Key Biomarkers and Patient Subgroups

Poster Pearl: A 2-Biomarker Class MCED Test Delivers High Specificity and Sensitivity

Poster Pearl: A 2-Biomarker Class MCED Test Delivers High Specificity and Sensitivity

Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer

Overcoming Barriers to Equitable Care in HNSCC

Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC

The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence

Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens

Overcoming Barriers to Equitable Care in HNSCC

Managing Immune-Related Adverse Events With Immunotherapies

Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC

The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence

Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens

Overcoming Barriers to Equitable Care in HNSCC

Managing Immune-Related Adverse Events With Immunotherapies

Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC

Indications to Switch Therapies for Myelofibrosis Patients

Indications to Switch Therapies for Myelofibrosis Patients